PhaseV's AI-Powered Trial Optimizer Debuts on AWS Marketplace, Revolutionizing Clinical Trial Design and Efficiency

Biopharma and CROs Gain Direct Access to PhaseV's Leading Platform to Accelerate Clinical Trials and Cut Costs by Up to 50%

BOSTON, July 10, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML for clinical development, today announced the launch of its Trial Optimizer platform, a key component of its holistic solution, on Amazon Web Services (AWS) Marketplace. This availability offers biopharma sponsors and Contract Research Organizations (CROs) an easy and efficient way to access PhaseV's platform to increase the probability of success, reduce sample size and trial duration, and drive more efficient and cost-effective clinical trials.

PhaseV's Trial Optimizer is an AI/ML-powered solution that helps sponsors design, explore, evaluate and optimize phase 1-3 clinical trial designs, including fixed, adaptive, or Bayesian methodologies. The platform seamlessly integrates multiple data sources, including sponsor-provided and external data, to account for complex trade-offs like cost, power, duration, probability of success, and adaptability.

"Bringing Trial Optimizer to AWS Marketplace is a significant milestone for us and, more importantly, for our customers across the globe," said Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV. "With a current failure rate of around 90%, using GenAI and machine learning to optimize clinical trial design is crucial. This new channel allows our customers to leverage AWS' secured infrastructure from anywhere in the world and easily access our robust AI/ML capabilities to accelerate their clinical development pipelines and bring promising therapies to patients faster."

The platform's proprietary algorithms provide optimized trial design recommendations, covering crucial aspects like sample size reduction, alpha allocation, and interim analysis timing. This enables teams to explore and compare multiple design scenarios, ensuring strategies align with their specific goals and constraints. To date, PhaseV has helped sponsors reduce patient recruitment and trial duration by up to 40%, cut development costs by as much as 50%, and increase the probability of success by over 30%.

Designed for multi-stakeholder use across clinical operations, biostatistics, clinical development and data science, PhaseV's Trial Optimizer promotes collaboration and joint decision-making. AWS Marketplace users will benefit from a range of features, including:

• Rapid Simulation Engine: Runs millions of simulations in minutes to optimize any trial design. Visual results support easy interpretation, and for adaptive designs, provide early insights into potential dynamic interventions like response-adaptive randomization, sample size re-estimation and arm dropping.
• Causal-to-Design: Seamlessly integrates insights from past trials and PhaseV's data lake to optimize inclusion/exclusion criteria and inform development considerations.
• Placebo Response Estimation: Instantly models average placebo response rates by leveraging relevant study data and real-world data.

These benefits of PhaseV's solution are now combined with the simplified procurement that AWS Marketplace offers through consolidated billing and predefined contractual agreements. Additional capabilities like virtual control arms and live trial monitoring dashboards are also available (currently not on AWS Marketplace).

About PhaseV

PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by 50%, decreased enrollment size and trial duration by 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.

Learn more at www.PhaseVTrials.com and follow us on LinkedIn.

Media Contact: 
Ellie Hanson
FINN Partners for PhaseV
[email protected]

Video: https://www.youtube.com/watch?v=0hVkC6jJWyM
Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg

SOURCE PhaseV